Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D (research and development) sector & industry count cost of Parliament stem cell objections

This article was originally published in Clinica

Executive Summary

The EU medical research community was put in a spin when the European Parliament voted at its session on April 9-10 to add series of amendments to the Commission's proposed directive on the safe sourcing of human tissues and cells. The delay represents a new hurdle for the medical devices industry, which is a regular user of human tissues and cells in products such as heart valves, vascular grafts and dermal replacements

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061852

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel